Neothetics (NEOT) Tops Q2 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Neothetics Reports Second Quarter 2015 Financial Results
August 13, 2015 8:00 AM EDTSAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ: NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the second quarter 2015.
"We remain on track for reporting topline results from our pivotal U.S. Phase 3 trials later this year," said George Mahaffey, president and chief executive officer of Neothetics. "There is clearly high demand for new, safe and effective FDA-approved drug options in the rapidly growing non-invasive body contouring market. If approved, LIPO-202 will be the first drug approved for reduction of central abdominal... More
Neothetics Reports Second Quarter 2015 Financial Results
August 13, 2015 8:00 AM EDTSAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ: NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the second quarter 2015.
"We remain on track for reporting topline results from our pivotal U.S. Phase 3 trials later this year," said George Mahaffey, president and chief executive officer of Neothetics. "There is clearly high demand for new, safe and effective FDA-approved drug options in the rapidly growing non-invasive body contouring market. If approved, LIPO-202 will be the first drug approved for reduction of central abdominal... More
